Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study

Mikhael F. El-Chami, Kyoko Soejima, Jonathan P. Piccini, Dwight Reynolds, Philippe Ritter, Toshimasa Okabe, Paul Andrew Friedman, Yong-Mei Cha, Kurt Stromberg, Reece Holbrook, Dedra H. Fagan, Paul R. Roberts

Research output: Contribution to journalArticle

Abstract

Background: The Micra clinical trials have enrolled more than 2500 patients without any reported device-related infections that required removal during follow-up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation. Objective: To analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow-up in patients with history of Micra leadless pacemaker implantation. Methods: SIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow-up. Results: Among patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram-positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram-positive bacteria), and gram-negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow-up. Conclusion: In this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.

Original languageEnglish (US)
JournalPACE - Pacing and Clinical Electrophysiology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Bacteremia
Incidence
Infection
Endocarditis
Anti-Bacterial Agents
Equipment and Supplies
Enterococcus
Gram-Positive Bacteria
Streptococcus
Staphylococcus
Documentation
Clinical Trials
Therapeutics

Keywords

  • bacteremia
  • endocarditis
  • leadless pacemakers
  • Micra

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Incidence and outcomes of systemic infections in patients with leadless pacemakers : Data from the Micra IDE study. / El-Chami, Mikhael F.; Soejima, Kyoko; Piccini, Jonathan P.; Reynolds, Dwight; Ritter, Philippe; Okabe, Toshimasa; Friedman, Paul Andrew; Cha, Yong-Mei; Stromberg, Kurt; Holbrook, Reece; Fagan, Dedra H.; Roberts, Paul R.

In: PACE - Pacing and Clinical Electrophysiology, 01.01.2019.

Research output: Contribution to journalArticle

El-Chami, Mikhael F. ; Soejima, Kyoko ; Piccini, Jonathan P. ; Reynolds, Dwight ; Ritter, Philippe ; Okabe, Toshimasa ; Friedman, Paul Andrew ; Cha, Yong-Mei ; Stromberg, Kurt ; Holbrook, Reece ; Fagan, Dedra H. ; Roberts, Paul R. / Incidence and outcomes of systemic infections in patients with leadless pacemakers : Data from the Micra IDE study. In: PACE - Pacing and Clinical Electrophysiology. 2019.
@article{9a809bc887e744aba381ec222e5976f0,
title = "Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study",
abstract = "Background: The Micra clinical trials have enrolled more than 2500 patients without any reported device-related infections that required removal during follow-up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation. Objective: To analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow-up in patients with history of Micra leadless pacemaker implantation. Methods: SIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow-up. Results: Among patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram-positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram-positive bacteria), and gram-negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow-up. Conclusion: In this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.",
keywords = "bacteremia, endocarditis, leadless pacemakers, Micra",
author = "El-Chami, {Mikhael F.} and Kyoko Soejima and Piccini, {Jonathan P.} and Dwight Reynolds and Philippe Ritter and Toshimasa Okabe and Friedman, {Paul Andrew} and Yong-Mei Cha and Kurt Stromberg and Reece Holbrook and Fagan, {Dedra H.} and Roberts, {Paul R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/pace.13752",
language = "English (US)",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Incidence and outcomes of systemic infections in patients with leadless pacemakers

T2 - Data from the Micra IDE study

AU - El-Chami, Mikhael F.

AU - Soejima, Kyoko

AU - Piccini, Jonathan P.

AU - Reynolds, Dwight

AU - Ritter, Philippe

AU - Okabe, Toshimasa

AU - Friedman, Paul Andrew

AU - Cha, Yong-Mei

AU - Stromberg, Kurt

AU - Holbrook, Reece

AU - Fagan, Dedra H.

AU - Roberts, Paul R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: The Micra clinical trials have enrolled more than 2500 patients without any reported device-related infections that required removal during follow-up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation. Objective: To analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow-up in patients with history of Micra leadless pacemaker implantation. Methods: SIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow-up. Results: Among patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram-positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram-positive bacteria), and gram-negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow-up. Conclusion: In this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.

AB - Background: The Micra clinical trials have enrolled more than 2500 patients without any reported device-related infections that required removal during follow-up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation. Objective: To analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow-up in patients with history of Micra leadless pacemaker implantation. Methods: SIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow-up. Results: Among patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram-positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram-positive bacteria), and gram-negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow-up. Conclusion: In this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.

KW - bacteremia

KW - endocarditis

KW - leadless pacemakers

KW - Micra

UR - http://www.scopus.com/inward/record.url?scp=85068518645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068518645&partnerID=8YFLogxK

U2 - 10.1111/pace.13752

DO - 10.1111/pace.13752

M3 - Article

C2 - 31232461

AN - SCOPUS:85068518645

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

ER -